Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors

Fineline Cube Jun 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Deals

Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development

Fineline Cube Jun 18, 2024

Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...

Company Drug

BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US

Fineline Cube Jun 18, 2024

BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...

Company Drug

Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials

Fineline Cube Jun 18, 2024

Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...

Company Drug

Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US

Fineline Cube Jun 18, 2024

Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...

Company Drug

MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma

Fineline Cube Jun 18, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company

AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer

Fineline Cube Jun 17, 2024

Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...

Company Drug

FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors

Fineline Cube Jun 17, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Deals

CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally

Fineline Cube Jun 17, 2024

CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...

Company Deals

Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round

Fineline Cube Jun 17, 2024

Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed...

Company Deals Drug

Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories

Fineline Cube Jun 17, 2024

Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...

Company Drug

CARsgen Therapeutics’ Saikaize and CT071 Show Strong Results in EHA Clinical Trials

Fineline Cube Jun 17, 2024

CARsgen Therapeutics, a biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 2171), has...

Company Drug

RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer

Fineline Cube Jun 14, 2024

RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...

Company Deals

AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701

Fineline Cube Jun 14, 2024

AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...

Company Deals

BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region

Fineline Cube Jun 14, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has...

Company Deals

Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository

Fineline Cube Jun 14, 2024

Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has...

Company Deals

Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil

Fineline Cube Jun 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co.,...

Company Drug

CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto

Fineline Cube Jun 14, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...

Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Posts pagination

1 … 336 337 338 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.